Spruce Biosciences

Spruce Biosciences, Inc operates as a late-stage biopharmaceutical company, which focuses on the development of novel therapies for rare diseases affecting the endocrine system. The firm is initially developing its wholly-owned product candidate, tildacerfont, as the non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia. The company was founded on November 13, 2014 and is headquartered in Daly City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Spruce Biosciences reports mixed trial results, eyes Phase III advancement

Spruce Biosciences faces a mixed performance in Phase II trials, with promising results in pediatric CAH patients but challenges in adult populations. Financially, the company is stable with a focus on cost-saving initiatives. Despite setbacks, opportunities exist in advancing tildacerfont for CAH treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. It focuses on developing its wholly owned product candidate, Tildacerfont. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences to Participate in September Investor Conferences

Spruce Biosciences to Participate in September Investor Conferences

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Announces Pediatric Classic CAH Program Details During Virtual R&D Day

Spruce Biosciences Announces Pediatric Classic CAH Program Details During Virtual R&D Day

Late-stage biopharmaceutical company Spruce Biosciences Inc (NASDAQ: SRPB) reported financial results for the second quarter ended June 30, 2021 and announced that it has submitted an investigational new drug application (IND) for tildacerfont in the treatment of polycystic ovary syndrome (PCOS), which has recently been cleared by the FDA. Tildacerfont is an investigational oral medication that binds to CRF1 receptors on the pituitary gland, preventing excessive production of adrenocorticotropic hormone (ACTH).

Spruce Biosciences Expands Tildacerfont Portfolio with Potential Treatment for Polycystic Ovary Syndrome

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. “As we continue to progress the execution of the CAHmelia clinical program in adults with classic congenital adrenal hyperplasia (CAH), we were also pleas

Spruce Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Updates

Spruce Biosciences is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Spruce Biosciences (SPRB)

F-Star Therapeutics Inc

Halozyme Therapeutics

Knnate Biopharma

Rubius Therapeutics Inc

Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.

5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates

Dr. Ways' Expertise in Late-Stage Clinical Development in Therapeutics Areas of High Unmet Medical Meet Supports Spruce's Goal to Expand Portfolio of Indications for Tildacerfont  San Francisco, Calif. – June 24, 2021 – Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced the appointment of Kirk Ways, M.D.

Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors.

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors

Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors

Tildacerfont was Evaluated in Two Phase 2 Open-Label Studies in Adults with Classic Congenital Adrenal Hyperplasia (CAH) Data Demonstrated Normalization or Trend to Normalization in Key Hormone Biomarkers

Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism.

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism

Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #ECE2021--Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23rd European Congress of Endocrinology

Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23rd European Congress of Endocrinology

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences to Participate in the RBC Capital Markets Global Healthcare Conference

Spruce Biosciences to Participate in the RBC Capital Markets Global Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Updates

Spruce Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Updates

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Recent Corporate Updates

Spruce Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Recent Corporate Updates

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #ENDO2021--Spruce Biosciences Presents Phase 1 and 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia from Endocrine Society's 2021 Annual Mtg

Spruce Biosciences Presents Phase 1 and 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia from Endocrine Society's 2021 Annual Meeting

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences to Announce Phase 1 and 2 Data of Tildacerfont at Endocrine Society's 2021 Annual Meeting

Spruce Biosciences to Announce Phase 1 and 2 Data of Tildacerfont at Endocrine Society's 2021 Annual Meeting

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences to Participate in Upcoming Investor Conferences

Spruce Biosciences to Participate in Upcoming Investor Conferences

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021

Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Added to Russell 2000®, 3000® and Microcap® Indexes

Spruce Biosciences Added to Russell 2000®, 3000® and Microcap® Indexes

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Spruce Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference

Spruce Biosciences to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Spruce Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

FuboTV

Intrusion

Kronos Bio

Mudrick Capital Acquisition

Shattuck Labs

U.S. IPO Weekly Recap: Healthcare Dominates A 7 IPO Week

Shares of Spruce Biosciences Inc. rallied in their public debut, as they opened 21% above the initial public offering price. The stock's first trade was at $18.14 at 11:37 a.m.

Spruce Biosciences stock opens more than 20% above its IPO price, then pulls back

Spruce Biosciences Inc. said Friday that its initial public offering, which was upsized by 20%, priced at $15 a share, as the California-based biopharmaceutical company developing treatments for endocrine disorders raised $90 million. The company said late Thursday that it sold 6.0 million shares in the IPO, up from an expected 5.0 million.

News for Spruce Biosciences Stock (SPRB)